CITED2 Fusion

CI-VAR-00001497Explore in graph →CIViC 5346

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Uterine Neoplasm1
ESR1::NCOA3 Fusion OR GREB1::NCOA2 Fusion OR ESR1::CITED2 Fusion OR ESR1::v Fusion OR GREB1::v Fusion	(prognostic)	Prognostic	C	Supports Poor Outcome	1	submitted	EID12707 In a retrospective UTROSCT cohort (n = 17, follow-up n = 13), 3 patients (23.1%) carrying GREB1::NCOA2, ESR1::NCOA3 or ESR1::CITED2 fusions developed pelvic, abdominal or pulmonary recurrence, with re… (full text at CIViC) PMID 38000680 · Qijun et al., 2024 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.